COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00075999" target="_blank" >RIV/65269705:_____/22:00075999 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00125822
Result on the web
<a href="https://ashpublications.org/blood/article/139/10/1588/477881/COVID-19-in-vaccinated-adult-patients-with" target="_blank" >https://ashpublications.org/blood/article/139/10/1588/477881/COVID-19-in-vaccinated-adult-patients-with</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2021014124" target="_blank" >10.1182/blood.2021014124</a>
Alternative languages
Result language
angličtina
Original language name
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Original language description
Coronavirus disease 2019 (COVID-19) is a life-threatening condition of high relevance for comorbid patients, such as those with baseline hematological malignancies (HM). In April 2020, the European Hematology Association - Infectious Diseases Working Party opened an open web-based registry to collect all cases of HM adult patients that developed COVID-19 infections (EPICOVIDEHA survey). This registry aimed to describe the epidemiology, risk factors, and mortality rates of HM patients. Overall, we collected 3801 valid cases, and we observed an overall mortality rate of 31%. Nearly 1 year after the first described COVID-19 case, in December 2020, the first vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were available,6,7 and administration to the highest risk populations including HM patients started.8,9 From 1 January 2021, we prospectively collected registry data on adult fully or partially vaccinated HM patients that developed COVID-19 to assess the vaccine efficacy and potentially identify categories of patients that may be less protected by vaccines. With this report, we share our findings of the first 113 patients included in the registry.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
1528-0020
Volume of the periodical
139
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
1588-1592
UT code for WoS article
000769559500020
EID of the result in the Scopus database
2-s2.0-85126389789